Clinical Trial Update: A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 623 in Subjects With Systemic Lupus Erythematosus [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety, pharmacokinetics and pharmacodynamics of AMG 623 in subjects with systemic lupus erythematosus has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• AMG 623

Snippet

Sponsor: Amgen | Conditions: Systemic Lupus Erythematosus | Phase 1 | Status: COMPLETED